Gradalis
Carrollton
About Gradalis
Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with Ewing's sarcoma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $77.8M
- Last round: Grant (Nov 2023)
- Website: gradalisinc.com
- Phone: 214-442-8100
Industries & Categories
Biotechnology, Health Diagnostics, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/gradalis-125290 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.